{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T21:50:33Z","timestamp":1791323433511,"version":"4.3.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2009,11,1]],"date-time":"2009-11-01T00:00:00Z","timestamp":1257033600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Endocrinol"],"published-print":{"date-parts":[[2009,11]]},"DOI":"10.1038\/nrendo.2009.197","type":"journal-article","created":{"date-parts":[[2009,10,21]],"date-time":"2009-10-21T08:24:44Z","timestamp":1256113484000},"page":"633-638","source":"Crossref","is-referenced-by-count":125,"title":["CB1 antagonists for obesity\u2014what lessons have we learned from rimonabant?"],"prefix":"10.1038","volume":"5","author":[{"given":"Vincenzo","family":"Di Marzo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Pierre","family":"Despr\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"issue":"Suppl. 1","key":"BFnrendo2009197_CR1","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.neuropharm.2004.07.030","volume":"47","author":"AC Howlett","year":"2004","unstructured":"Howlett, A. C.  et al. Cannabinoid physiology and pharmacology: 30 years of progress. Neuropharmacology 47 (Suppl. 1), 345\u2013358 (2004).","journal-title":"Neuropharmacology"},{"key":"BFnrendo2009197_CR2","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1126\/science.1470919","volume":"258","author":"WA Devane","year":"1992","unstructured":"Devane, W. A.  et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258, 1946\u20131949 (1992).","journal-title":"Science"},{"key":"BFnrendo2009197_CR3","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1007\/s00125-008-1048-2","volume":"51","author":"V Di Marzo","year":"2008","unstructured":"Di Marzo, V. The endocannabinoid system in obesity and type 2 diabetes. Diabetologia 51, 1356\u20131367 (2008).","journal-title":"Diabetologia"},{"key":"BFnrendo2009197_CR4","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/0091-3057(86)90144-9","volume":"25","author":"RW Foltin","year":"1986","unstructured":"Foltin, R. W., Brady, J. V. & Fischman, M. W. Behavioral analysis of marijuana effects on food intake in humans. Pharmacol. Biochem. Behav. 25, 577\u2013582 (1986).","journal-title":"Pharmacol. Biochem. Behav."},{"key":"BFnrendo2009197_CR5","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1016\/S0140-6736(05)66374-X","volume":"365","author":"LF Van Gaal","year":"2005","unstructured":"Van Gaal, L. F.  et al. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 365, 1389\u20131397 (2005).","journal-title":"Lancet"},{"key":"BFnrendo2009197_CR6","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1056\/NEJMoa044537","volume":"353","author":"JP Despr\u00e9s","year":"2005","unstructured":"Despr\u00e9s, J. P.  et al. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N. Engl. J. Med. 353, 2121\u20132134 (2005).","journal-title":"N. Engl. J. Med."},{"key":"BFnrendo2009197_CR7","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1016\/S0140-6736(06)69571-8","volume":"368","author":"AJ Scheen","year":"2006","unstructured":"Scheen, A. J.  et al. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet 368, 1660\u20131672 (2006).","journal-title":"Lancet"},{"key":"BFnrendo2009197_CR8","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1001\/jama.295.7.761","volume":"295","author":"FX Pi-Sunyer","year":"2006","unstructured":"Pi-Sunyer, F. X.  et al. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 295, 761\u2013775 (2006).","journal-title":"JAMA"},{"key":"BFnrendo2009197_CR9","volume-title":"Cochrane Database of Systematic Reviews","author":"K Cahill","year":"2009","unstructured":"Cahill, K. & Ussher, M. Cannabinoid type 1 receptor antagonists (rimonabant) for smoking cessation. Cochrane Database of Systematic Reviews, Issue 3. Art. No.: CD005353 10.1002\/14651858.CD005353.pub3 (2009)."},{"key":"BFnrendo2009197_CR10","doi-asserted-by":"crossref","unstructured":"Prospective Studies Collaboration. Body-mass index and cause-specific mortality in 900,000 adults: collaborative analyzes of 57 prospective studies. Lancet 373, 1083\u20131096 (2009).","DOI":"10.1016\/S0140-6736(09)60318-4"},{"key":"BFnrendo2009197_CR11","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1038\/nature05488","volume":"444","author":"JP Despr\u00e9s","year":"2006","unstructured":"Despr\u00e9s, J. P. & Lemieux, I. Abdominal obesity and metabolic syndrome. Nature 444, 881\u2013887 (2006).","journal-title":"Nature"},{"key":"BFnrendo2009197_CR12","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1161\/ATVBAHA.107.159228","volume":"28","author":"JP Despr\u00e9s","year":"2008","unstructured":"Despr\u00e9s, J. P.  et al. Abdominal obesity and the metabolic syndrome: contribution to global cardiometabolic risk. Arterioscler. Thromb. Vasc. Biol. 28, 1039\u20131049 (2008).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"BFnrendo2009197_CR13","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1136\/bmj.322.7288.716","volume":"322","author":"JP Despr\u00e9s","year":"2001","unstructured":"Despr\u00e9s, J. P., Lemieux, I. & Prud'homme, D. Treatment of obesity: need to focus on high risk abdominally obese patients. BMJ 322, 716\u2013720 (2001).","journal-title":"BMJ"},{"key":"BFnrendo2009197_CR14","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1136\/bmj.322.7299.1379","volume":"322","author":"JP Despr\u00e9s","year":"2001","unstructured":"Despr\u00e9s, J. P. Drug treatment for obesity. We need more studies in men at higher risk of coronary events. BMJ 322, 1379\u20131380 (2001).","journal-title":"BMJ"},{"key":"BFnrendo2009197_CR15","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1136\/bmj.39385.413113.25","volume":"335","author":"D Rucker","year":"2007","unstructured":"Rucker, D., Padwal, R., Li, S. K., Curioni, C. & Lau, D. C. Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ 335, 1194\u20131199 (2007).","journal-title":"BMJ"},{"key":"BFnrendo2009197_CR16","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.numecd.2006.07.005","volume":"17","author":"SA Ritchie","year":"2007","unstructured":"Ritchie, S. A. & Connell, J. M. The link between abdominal obesity, metabolic syndrome and cardiovascular disease. Nutr. Metab. Cardiovasc. Dis. 17, 319\u2013326 (2007).","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"key":"BFnrendo2009197_CR17","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1111\/j.1467-789X.2009.00567.x","volume":"10","author":"AN Fabricatore","year":"2009","unstructured":"Fabricatore, A. N.  et al. Attrition from randomized controlled trials of pharmacological weight loss agents: a systematic review and analysis. Obes. Rev. 10, 333\u2013341 (2009).","journal-title":"Obes. Rev."},{"key":"BFnrendo2009197_CR18","doi-asserted-by":"publisher","first-page":"3053","DOI":"10.2337\/db06-0812","volume":"55","author":"M Bl\u00fcher","year":"2006","unstructured":"Bl\u00fcher, M.  et al. Dysregulation of the peripheral and adipose tissue endocannabinoid system in human abdominal obesity. Diabetes 55, 3053\u20133060 (2006).","journal-title":"Diabetes"},{"key":"BFnrendo2009197_CR19","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s00125-008-1178-6","volume":"52","author":"V Di Marzo","year":"2009","unstructured":"Di Marzo, V.  et al. Changes in plasma endocannabinoid levels in viscerally obese men following a 1 year lifestyle modification program and waist circumference reduction: associations with changes in metabolic risk factors. Diabetologia 52, 213\u2013217 (2009).","journal-title":"Diabetologia"},{"key":"BFnrendo2009197_CR20","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1001\/jama.299.13.1547","volume":"299","author":"SE Nissen","year":"2008","unstructured":"Nissen, S. E.  et al. Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial. JAMA 299, 1547\u20131560 (2008).","journal-title":"JAMA"},{"key":"BFnrendo2009197_CR21","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/S1567-5688(08)70044-8","volume":"9","author":"RD Carr","year":"2008","unstructured":"Carr, R. D.  et al. A two-year study to assess the efficacy, safety, and tolerability of taranabant in obese patients: 52 week results. Atherosclerosis 9, 12 (2008).","journal-title":"Atherosclerosis"},{"key":"BFnrendo2009197_CR22","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s00281-009-0145-8","volume":"31","author":"P Pacher","year":"2009","unstructured":"Pacher, P. & Steffens, S. The emerging role of the endocannabinoid system in cardiovascular disease. Semin. Immunopathol. 31, 63\u201377 (2009).","journal-title":"Semin. Immunopathol."},{"key":"BFnrendo2009197_CR23","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1093\/eurheartj\/ehn076","volume":"29","author":"LF Van Gaal","year":"2008","unstructured":"Van Gaal, L. F.  et al. Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe Study. Eur. Heart J. 29, 1761\u20131771 (2008).","journal-title":"Eur. Heart J."},{"key":"BFnrendo2009197_CR24","doi-asserted-by":"publisher","first-page":"3160","DOI":"10.1172\/JCI34827","volume":"118","author":"D Osei-Hyiaman","year":"2008","unstructured":"Osei-Hyiaman, D.  et al. Hepatic CB1 receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in mice. J. Clin. Invest. 118, 3160\u20133169 (2008).","journal-title":"J. Clin. Invest."},{"key":"BFnrendo2009197_CR25","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1038\/nm1775","volume":"14","author":"C Buettner","year":"2008","unstructured":"Buettner, C.  et al. Leptin controls adipose tissue lipogenesis via central, STAT3-independent mechanisms. Nat. Med. 14, 667\u2013675 (2008).","journal-title":"Nat. Med."}],"container-title":["Nature Reviews Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrendo.2009.197","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrendo.2009.197.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrendo.2009.197.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T03:32:17Z","timestamp":1684467137000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrendo.2009.197"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,11]]},"references-count":25,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2009,11]]}},"alternative-id":["BFnrendo2009197"],"URL":"https:\/\/doi.org\/10.1038\/nrendo.2009.197","relation":{},"ISSN":["1759-5029","1759-5037"],"issn-type":[{"value":"1759-5029","type":"print"},{"value":"1759-5037","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,11]]}}}